|
1
|
Yu ZJ, Yan HL, Xu FH, Chao HC, Deng LH, Xu
XD, Huang JB and Zeng T: Efficacy and side effects of drugs
commonly used for the treatment of lower urinary tract symptoms
associated with benign prostatic hyperplasia. Front Pharmacol.
11(658)2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Lee C, Kozlowski JM and Grayhack JT:
Intrinsic and extrinsic factors controlling benign prostatic
growth. Prostate. 31:131–138. 1997.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Yoo S, Oh S, Park J, Cho SY, Cho MC, Jeong
H and Son H: The impacts of metabolic syndrome and lifestyle on the
prevalence of benign prostatic hyperplasia requiring treatment:
Historical cohort study of 130 454 men. BJU Int. 123:140–148.
2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Calogero AE, Burgio G, Condorelli RA,
Cannarella R and La Vignera S: Epidemiology and risk factors of
lower urinary tract symptoms/benign prostatic hyperplasia and
erectile dysfunction. Aging Male. 22:12–19. 2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Egan KB: The epidemiology of benign
prostatic hyperplasia associated with lower urinary tract symptoms:
Prevalence and incident rates. Urol Clin North Am. 43:289–297.
2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Gacci M, Andersson KE, Chapple C, Maggi M,
Mirone V, Oelke M, Porst H, Roehrborn C, Stief C and Giuliano F:
Latest evidence on the use of phosphodiesterase type 5 inhibitors
for the treatment of lower urinary tract symptoms secondary to
benign prostatic hyperplasia. Eur Urol. 70:124–133. 2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Speakman MJ: PDE5 inhibitors in the
treatment of LUTS. Curr Pharm Des. 15:3502–3505. 2009.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Broderick GA: Oral pharmacotherapy and the
contemporary evaluation and management of erectile dysfunction. Rev
Urol. 5 (Suppl 7):S9–S20. 2003.PubMed/NCBI
|
|
9
|
Li MK, Garcia L, Patron N, Moh LC, Sundram
M, Leungwattanakij S, Pripatnanont C, Cheng C, Chi-Wai M and
Loi-Cheong N: An Asian multinational prospective observational
registry of patients with benign prostatic hyperplasia, with a
focus on comorbidities, lower urinary tract symptoms and sexual
function. BJU Int. 101:197–202. 2008.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Maurice DH, Ke H, Ahmad F, Wang Y, Chung J
and Manganiello VC: Advances in targeting cyclic nucleotide
phosphodiesterases. Nat Rev Drug Discov. 13:290–314.
2014.PubMed/NCBI View
Article : Google Scholar
|
|
11
|
Keravis T and Lugnier C: Cyclic nucleotide
phosphodiesterase (PDE) isozymes as targets of the intracellular
signalling network: Benefits of PDE inhibitors in various diseases
and perspectives for future therapeutic developments. Br J
Pharmacol. 165:1288–1305. 2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Murthy KS: Signaling for contraction and
relaxation in smooth muscle of the gut. Annu Rev Physiol.
68:345–374. 2006.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wroński S: The new horizons of
pharmacotherapy. Unexpected pharmacological actions and a new
therapeutic strategy of phosphodiesterase-5 inhibitors. Cent
European J Urol. 67:314–318. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Gacci M, Corona G, Salvi M, Vignozzi L,
McVary KT, Kaplan SA, Roehrborn CG, Serni S, Mirone V, Carini M and
Maggi M: A systematic review and meta-analysis on the use of
phosphodiesterase 5 inhibitors alone or in combination with
α-blockers for lower urinary tract symptoms due to benign prostatic
hyperplasia. Eur Urol. 61:994–1003. 2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Lin CS, Lin G, Xin ZC and Lue TF:
Expression, distribution and regulation of phosphodiesterase 5.
Curr Pharm Des. 12:3439–3457. 2006.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Zucchi A, Costantini E, Scroppo FI,
Silvani M, Kopa Z, Illiano E, Petrillo MG, Cari L and Nocentini G:
The first-generation phosphodiesterase 5 inhibitors and their
pharmacokinetic issue. Andrology. 7:804–817. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Lin CS, Chow S, Lau A, Tu R and Lue TF:
Human PDE5A gene encodes three PDE5 isoforms from two alternate
promoters. Int J Impot Res. 14:15–24. 2002.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Aguiar S, van der Gaag B and Cortese FAB:
RNAi mechanisms in Huntington's disease therapy: siRNA versus
shRNA. Transl Neurodegener. 6(30)2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Pan YG, Liu JH, Zhan Y, Wang T, Wan ZH, Li
ZY and Liu Y: Impact of rAd5-shRNA-PDE5A3 on cGMP in the smooth
muscle cells of human corpus cavernosum. Zhonghua Nan Ke Xue.
15:689–692. 2009.PubMed/NCBI(In Chinese).
|
|
20
|
Henry GH, Malewska A, Joseph DB, Malladi
VS, Lee J, Torrealba J, Mauck RJ, Gahan JC, Raj GV, Roehrborn CG,
et al: A cellular anatomy of the normal adult human prostate and
prostatic urethra. Cell Rep. 25:3530–3542.e5. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Li C, Ye L, Yang L, Yu X, He Y, Chen Z, Li
L and Zhang D: Rapamycin promotes the survival and adipogenesis of
ischemia-challenged adipose derived stem cells by improving
autophagy. Cell Physiol Biochem. 44:1762–1774. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Gacci M, Ficarra V, Sebastianelli A,
Corona G, Serni S, Shariat SF, Maggi M, Zattoni F, Carini M and
Novara G: Impact of medical treatments for male lower urinary tract
symptoms due to benign prostatic hyperplasia on ejaculatory
function: A systematic review and meta-analysis. J Sex Med.
11:1554–1566. 2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Fwu CW, Eggers PW, Kirkali Z, McVary KT,
Burrows PK and Kusek JW: Change in sexual function in men with
lower urinary tract symptoms/benign prostatic hyperplasia
associated with long-term treatment with doxazosin, finasteride and
combined therapy. J Urol. 191:1828–1834. 2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Carvalheira A, Forjaz V and Pereira NM:
Adherence to phosphodiesterase type 5 inhibitors in the treatment
of erectile dysfunction in long-term users: How do men use the
inhibitors? Sex Med. 2:96–102. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
26
|
Tinel H, Stelte-Ludwig B, Hütter J and
Sandner P: Pre-clinical evidence for the use of phosphodiesterase-5
inhibitors for treating benign prostatic hyperplasia and lower
urinary tract symptoms. BJU Int. 98:1259–1263. 2006.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Gacci M, Salvi M, Sebastianelli A,
Vignozzi L, Corona G, McVary KT, Kaplan SA, Maggi M, Carini M and
Oelke M: The use of a single daily dose of tadalafil to treat signs
and symptoms of benign prostatic hyperplasia and erectile
dysfunction. Res Rep Urol. 5:99–111. 2013.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Chrysant SG: Effectiveness and safety of
phosphodiesterase 5 inhibitors in patients with cardiovascular
disease and hypertension. Curr Hypertens Rep. 15:475–483.
2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Rashid A: The efficacy and safety of PDE5
inhibitors. Clin Cornerstone. 7:47–56. 2005.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Paul M, Murphy SF, Hall C, Schaeffer AJ
and Thumbikat P: Protease-activated receptor 2 activates
CRAC-mediated Ca2+ influx to cause prostate smooth
muscle contraction. FASEB Bioadv. 1:255–264. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Brozovich FV, Nicholson CJ, Degen CV, Gao
YZ, Aggarwal M and Morgan KG: Mechanisms of vascular smooth muscle
contraction and the basis for pharmacologic treatment of smooth
muscle disorders. Pharmacol Rev. 68:476–532. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Shi YF, Yu DJ, Jiang CY, Wang XJ, Zhu YP,
Zhao RZ, Lv Z and Sun XW: TRAF6 regulates proliferation of stromal
cells in the transition and peripheral zones of benign prostatic
hyperplasia via Akt/mTOR signaling. Prostate. 78:193–201.
2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Chen P, Yin J, Guo YM, Xiao H, Wang XH,
DiSanto ME and Zhang XH: The expression and functional activities
of smooth muscle myosin and non-muscle myosin isoforms in rat
prostate. J Cell Mol Med. 22:576–588. 2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Wang X, Wang Y, Gratzke C, Sterr C, Yu Q,
Li B, Strittmatter F, Herlemann A, Tamalunas A, Rutz B, et al:
Ghrelin aggravates prostate enlargement in rats with
testosterone-induced benign prostatic hyperplasia, stromal cell
proliferation, and smooth muscle contraction in human prostate
tissues. Oxid Med Cell Longev. 2019(4748312)2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Elliot SJ, Zorn BH, McLeod DG, Moul JW,
Nyberg L, Striker LJ and Striker GE: Pentosan polysulfate decreases
prostate smooth muscle proliferation and extracellular matrix
turnover. Prostate Cancer Prostatic Dis. 6:138–142. 2003.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Wharton J, Strange JW, Møller GM, Growcott
EJ, Ren X, Franklyn AP, Phillips SC and Wilkins MR:
Antiproliferative effects of phosphodiesterase type 5 inhibition in
human pulmonary artery cells. Am J Respir Crit Care Med.
172:105–113. 2005.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Chen L, Daum G, Chitaley K, Coats SA,
Bowen-Pope DF, Eigenthaler M, Thumati NR, Walter U and Clowes AW:
Vasodilator-stimulated phosphoprotein regulates proliferation and
growth inhibition by nitric oxide in vascular smooth muscle cells.
Arterioscler Thromb Vasc Biol. 24:1403–1408. 2004.PubMed/NCBI View Article : Google Scholar
|
